Xeris Biopharma Holdings Inc. Stock
Xeris Biopharma Holdings Inc. gained 1.870% today.
Xeris Biopharma Holdings Inc. is currently one of the favorites of our community with 8 Buy predictions and no Sell predictions.
With a target price of 8 € there is a slightly positive potential of 12.71% for Xeris Biopharma Holdings Inc. compared to the current price of 7.1 €.
Pros and Cons of Xeris Biopharma Holdings Inc. in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
S********** s********
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xeris Biopharma Holdings Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xeris Biopharma Holdings Inc. | 1.870% | -1.988% | -0.977% | 47.506% | 12.399% | 190.902% | 194.279% |
| Evolus Inc | -0.880% | -4.599% | -13.132% | -33.084% | -4.844% | -41.730% | -44.237% |
| Heron Therapeutics Inc. | -1.530% | 4.313% | 19.752% | -70.510% | -60.054% | -70.530% | -95.574% |
| Rhythm Pharmaceuticals | -1.680% | -6.383% | -10.660% | 15.033% | -5.882% | 303.670% | 547.059% |
Comments
Xeris Biopharma (XERS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $10.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Show more
Ratings data for XERS provided by MarketBeat